Chemo-Free hope: new drug cocktail targets aggressive lymphoma
NCT ID NCT07231250
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II trial is testing a combination of three drugs—glofitamab, polatuzumab vedotin, and zuberitamab—in 40 people newly diagnosed with diffuse large B-cell lymphoma. The goal is to see if this chemo-free approach can achieve complete remission early in treatment. Participants will receive the drugs intravenously over several cycles, with the main focus on how many achieve remission by the fourth cycle.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Glofitamab, polatuzumab vedotin, and zuberitamab (drug combination)
- What this could lead to
- If successful, this could offer a chemotherapy-free treatment option for newly diagnosed diffuse large B-cell lymphoma, potentially improving remission rates.
- What could go wrong
- This is an early Phase II study with only 40 participants, so results may not apply to all patients. Side effects from the drug combination are possible and not yet fully known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BISPECIFIC ANTIBODY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Pronged attack beat brain lymphoma?
- Can a new drug combo outsmart resistant lymphomas?
- Can a targeted drug boost standard chemo for aggressive lymphoma?
- Can a targeted drug combo outsmart an aggressive lymphoma?
- Can a reshaped chemo combo tame lymphoma with fewer side effects?
- New drug cocktail aims to outsmart aggressive blood cancer